OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TPIA58

Chandra Asri Pacific PT Tbk

Commodity ChemicalsVerified

Chandra Asri Pacific PT Tbk has a liquidity position that is below the industry median, with a current ratio of 4.21 and a debt-to-equity ratio of 0.69. The company's cash and equivalents amount to $497.2 million, but this is insufficient to cover its long-term debt of $1.88 billion, resulting in a negative net cash position. The company's free cash flow is negative at -$87.6 million, indicating a cash outflow from operations after capital expenditures. The company's profitability is weak, with a return on equity of -1.22% and a return on assets of -0.62%. These metrics are significantly below the industry median for commodity chemicals, which typically exhibit positive returns. The operating income is negative at -$29.3 million, and the net income is also negative at -$33.1 million, reflecting a challenging operating environment. Chandra Asri Pacific PT Tbk's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company does not provide detailed geographic revenue breakdowns, but its operations are primarily based in Indonesia. This concentration increases exposure to regional economic and regulatory risks. The company's growth trajectory is uncertain, with no analyst estimates indicating a strong buy or buy recommendation. The mean recommendation is 4.00, which is a sell rating, and one analyst has issued a sell recommendation. The company's revenue for the latest period is $471.9 million, but there is no clear indication of growth in the next fiscal year. The risk assessment for Chandra Asri Pacific PT Tbk indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position is a key flag, and the absence of a positive operating cash flow exacerbates this risk. The company has not issued any recent equity, and there is no indication of near-term dilution pressure. Recent events and filings do not provide significant insight into the company's strategic direction. The company's financial statements show a continued decline in profitability, and there are no recent transcripts or press releases indicating a turnaround strategy. The company's capital expenditures are negative, suggesting a reduction in investment in new projects.

30-day price · TPIA-450.00 (-9.5%)
Low$3910.00High$6800.00Close$4300.00As of13 May, 00:00 UTC
Profile
CompanyChandra Asri Pacific PT Tbk
TickerTPIA.JK
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Chandra Asri Pacific PT Tbk is a chemical manufacturing company that produces commodity chemicals and generates revenue primarily through the sale of chemical products.

Classification. Chandra Asri Pacific PT Tbk is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry with a confidence level of 0.92.

Chandra Asri Pacific PT Tbk has a liquidity position that is below the industry median, with a current ratio of 4.21 and a debt-to-equity ratio of 0.69. The company's cash and equivalents amount to $497.2 million, but this is insufficient to cover its long-term debt of $1.88 billion, resulting in a negative net cash position. The company's free cash flow is negative at -$87.6 million, indicating a cash outflow from operations after capital expenditures. The company's profitability is weak, with a return on equity of -1.22% and a return on assets of -0.62%. These metrics are significantly below the industry median for commodity chemicals, which typically exhibit positive returns. The operating income is negative at -$29.3 million, and the net income is also negative at -$33.1 million, reflecting a challenging operating environment. Chandra Asri Pacific PT Tbk's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company does not provide detailed geographic revenue breakdowns, but its operations are primarily based in Indonesia. This concentration increases exposure to regional economic and regulatory risks. The company's growth trajectory is uncertain, with no analyst estimates indicating a strong buy or buy recommendation. The mean recommendation is 4.00, which is a sell rating, and one analyst has issued a sell recommendation. The company's revenue for the latest period is $471.9 million, but there is no clear indication of growth in the next fiscal year. The risk assessment for Chandra Asri Pacific PT Tbk indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position is a key flag, and the absence of a positive operating cash flow exacerbates this risk. The company has not issued any recent equity, and there is no indication of near-term dilution pressure. Recent events and filings do not provide significant insight into the company's strategic direction. The company's financial statements show a continued decline in profitability, and there are no recent transcripts or press releases indicating a turnaround strategy. The company's capital expenditures are negative, suggesting a reduction in investment in new projects.
Key takeaways
  • Chandra Asri Pacific PT Tbk has a weak profitability profile, with negative returns on equity and assets.
  • The company's liquidity position is concerning, with a negative net cash position and a high debt-to-equity ratio.
  • Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
  • Analysts have issued a sell recommendation, with no positive outlook for the company's stock.
  • The company's capital expenditures are negative, indicating a reduction in investment.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$471.9M
Gross profit$520.0k
Operating income-$29.3M
Net income-$33.1M
R&D
SG&A
D&A
SBC
Operating cash flow-$387.2M
CapEx-$82.2M
Free cash flow-$87.6M
Total assets$5.37B
Total liabilities$2.66B
Total equity$2.71B
Cash & equivalents$497.2M
Long-term debt$1.88B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$2.58B$253.6M$152.0M$66.7M
FY-3$2.38B-$116.2M-$149.5M-$177.2M
FY-2$2.16B-$27.9M-$32.9M-$44.3M
FY-1$1.79B-$56.7M-$68.6M-$376.6M
FY0$7.02B$1.29B$1.09B$865.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$4.99B$2.93B$580.6M
FY-3$4.93B$2.81B$801.3M
FY-2$5.61B$2.74B$601.7M
FY-1$5.66B$2.64B$807.2M
FY0$12.32B$3.73B$1.24B
PeriodOCFCapExFCFSBC
FY-4$221.9M-$80.9M$66.7M
FY-3-$249.4M-$114.3M-$177.2M
FY-2$132.4M-$96.3M-$44.3M
FY-1-$159.2M-$405.1M-$376.6M
FY0$349.9M-$736.4M$865.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$471.9M-$29.3M-$33.1M-$87.6M
FQ-6$394.6M-$12.6M-$13.9M-$63.3M
FQ-5$365.1M$81.6M$77.3M-$40.6M
FQ-4$553.8M-$8.0M-$8.7M-$88.9M
FQ-3$622.1M-$23.2M-$25.6M-$75.0M
FQ-2$2.29B$1.61B$1.29B$1.61B
FQ-1$2.19B$460.8M$520.2M$372.5M
FQ0$1.92B-$262.9M-$207.4M-$541.5M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$5.37B$2.71B$497.2M
FQ-6$5.23B$2.66B$387.2M
FQ-5$5.35B$2.64B$585.4M
FQ-4$5.66B$2.64B$807.2M
FQ-3$6.06B$2.61B$307.4M
FQ-2$10.68B$3.87B$2.24B
FQ-1$10.97B$3.92B$1.06B
FQ0$12.32B$3.73B$1.24B
PeriodOCFCapExFCFSBC
FQ-7-$387.2M-$82.2M-$87.6M
FQ-6-$309.1M-$158.6M-$63.3M
FQ-5-$460.3M-$277.3M-$40.6M
FQ-4-$159.2M-$405.1M-$88.9M
FQ-3-$318.8M-$75.5M-$75.0M
FQ-2-$118.3M-$181.9M$1.61B
FQ-1$75.3M-$368.0M$372.5M
FQ0$349.9M-$736.4M-$541.5M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.71B
Net cash-$1.38B
Current ratio4.2
Debt/Equity0.7
ROA-0.6%
ROE-1.2%
Cash conversion11.7%
CapEx/Revenue-17.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 4 companies
MetricTPIAActivity
Op margin-6.2%8.0% medp25 -2.2% · p75 23.4%bottom quartile
Net margin-7.0%5.5% medp25 -3.8% · p75 18.5%bottom quartile
Gross margin0.1%20.5% medp25 12.4% · p75 29.7%bottom quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-17.4%8.6% medp25 1.7% · p75 15.7%bottom quartile
Debt / equity69.0%37.1% medp25 10.3% · p75 82.0%above median
Observations
IR observations
Mean recommendation4.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count0.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate0.00 USD
Last actual EPS0.02 USD
Mean revenue estimate6,624,000,000 USD
Last actual revenue9,163,127,000 USD
Mean EBIT estimate79,076,000 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-01 07:26 UTC#f5ea07c6
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 18:36 UTCJob: ef4af7cd